REDOX LIMITED (RDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RDX

RDX - REDOX LIMITED

Year End: June
GICS Industry Group : Capital Goods
Debt/EBITDA: 0.28
Index: ASX300 | ALL-ORDS

Redox is a distributor of chemicals, ingredients and raw materials to industrial and consumer-product manufacturers, with operations across Australia, New Zealand, Asia and North America.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.43

27 Aug
2026

-0.040

OPEN

$3.40

-1.15%

HIGH

$3.49

200,445

LOW

$3.40

TARGET
$3.883 13.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AIM . AL3 . ANN . ASB . CUP . DGL . IMB . KPG . SRV .
FNARENA'S MARKET CONSENSUS FORECASTS
RDX: 1
Title FY25
Actual
FY26
Actual
FY27
Forecast
FY28
Forecast
EPS (cps) xxx 17.5 19.0 xxx
DPS (cps) xxx 13.0 13.3 xxx
EPS Growth xxx 19.2% 8.6% xxx
DPS Growth xxx 4.0% 2.3% xxx
PE Ratio xxx N/A 17.8 xxx
Dividend Yield xxx N/A 3.9% xxx
Div Pay Ratio(%) xxx 74.3% 70.0% xxx

Dividend yield today if purchased 3 years ago: 5.04%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.83

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 25/08 - ex-div 6.50c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx17.5
DPS All xxxxxxxxxxxxxxx13.0
Sales/Revenue xxxxxxxxxxxxxxx1,330.2 M
Book Value Per Share xxxxxxxxxxxxxxx107.1
Net Operating Cash Flow xxxxxxxxxxxxxxx87.8 M
Net Profit Margin xxxxxxxxxxxxxxx6.91 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx16.61 %
Return on Invested Capital xxxxxxxxxxxxxxx15.94 %
Return on Assets xxxxxxxxxxxxxxx12.33 %
Return on Equity xxxxxxxxxxxxxxx16.61 %
Return on Total Capital xxxxxxxxxxxxxxx25.43 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx16.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx26 M
Long Term Debt xxxxxxxxxxxxxxx19 M
Total Debt xxxxxxxxxxxxxxx45 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx123 M
Price To Book Value xxxxxxxxxxxxxxx3.71

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx3.4 M
Capex % of Sales xxxxxxxxxxxxxxx0.26 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,032 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx145 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

21/08/2026

3

Equal-weight

$3.90

13.70%

Morgan Stanley sees Redox entering FY27 with positive momentum after resilient FY26 organic volume growth and well-controlled costs, with delayed chemical price inflation now providing a tailwind into 1H27.

The broker highlights accelerating organic growth, 34% US growth and potential North American M&A, but remains cautious about forecasting earnings beyond FY27 given uncertainty around pricing and gross margin normalisation.

FY27 EPS are raised by 5% but FY28 forecasts are tweaked lower by -1%, noting the longer-term sustainable growth rate remains difficult to determine.

The broker remains Equal-weight on valuation with a $3.90 target, down from $4. Industry view: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY27 dividend of 11.90 cents and EPS of 18.00 cents.
Morgan Stanley forecasts a full year FY28 dividend of 12.50 cents and EPS of 19.00 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

RDX STOCK CHART